Merck & Company (MRK) 57.88 $MRK
Bristol-Myers Lung Cancer Drug Opdivo Wins Speedy OK
at Investor's Business Daily - Wed Mar 04, 2:28PM CST
The Food and Drug Administration approved Bristol-Myers Squibb's (BMY) PD-1 inhibitor Opdivo for squamous-cell lung cancer Wednesday, well ahead of the expected timeline. The stock jumped to a 14-year high near 65. Opdivo was first approved for...
AZN: 67.79 (-0.49), MRK: 57.88 (-0.46), BMY: 65.67 (+3.75)
Bristol-Myers Backs Bavarian Nordic Cancer Vaccine
at Investor's Business Daily - Wed Mar 04, 10:12AM CST
Big pharma Bristol-Myers Squibb (BMY) said Wednesday that it inked a deal worth up to $975 million with Danish biotech Bavarian Nordic for its prostate-cancer vaccine candidate Prostvac, a step forward for a technology that still has yet to prove...
AZN: 67.79 (-0.49), MRK: 57.88 (-0.46), BMY: 65.67 (+3.75)
Geron's Q4 Loss Narrows Y/Y, Announces Restructuring Plan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 9:50AM CST
Geron Corporation (GERN) reported a fourth-quarter 2014 loss of 6 cents per share, a penny narrower than the year-ago loss of 7 cents. The Zacks Consensus Estimate was earnings of 17 cents.
JNJ: 101.65 (-0.69), GERN: 2.81 (-0.15), MRK: 57.88 (-0.46), BMY: 65.67 (+3.75)
Amgen: The Best Biotech Stock You Don't Own
Dan Strack - at Seeking Alpha - Tue Mar 03, 4:04PM CST
BIIB: 414.13 (+1.34), GILD: 103.06 (+0.27), PFE: 34.64 (+0.08), MRK: 57.88 (-0.46), AMGN: 159.19 (+0.63), ABBV: 60.27 (+0.65), GSK: 47.82 (+0.11), BMY: 65.67 (+3.75), HSP: 87.95 (+0.24), NVS: 99.04 (-0.02), CELG: 119.57 (+1.10)
5 Common Errors Of A Dividend Growth Forecast
Kurtis Hemmerling - at Seeking Alpha - Tue Mar 03, 7:52AM CST
HI: 31.17 (-0.71), RF: 9.55 (-0.07), HSY: 101.53 (-1.02), GPC: 94.04 (-1.47), CAG: 34.52 (-0.44), ED: 61.87 (-0.30), SYY: 38.81 (-0.09), RRD: 19.54 (+0.23), GWW: 236.00 (-5.29), TGT: 77.72 (-0.28), LOW: 74.02 (-0.99), BCR: 167.66 (+0.48), PFE: 34.64 (+0.08), VFC: 76.49 (-0.20), FDO: 78.59 (-0.07), MHFI: 102.55 (-1.07), MO: 55.79 (-0.67), WBA: 83.02 (-0.19), ADP: 86.57 (-2.13), ADM: 47.08 (-0.44), SIAL: 138.13 (-0.07), MRK: 57.88 (-0.46), MCD: 100.25 (+0.51), DOV: 71.63 (-0.50), CTL: 36.25 (-1.43), MMM: 167.16 (-1.11), TE: 19.23 (-0.05), GE: 25.66 (-0.20), BDX: 148.36 (+2.10), HBAN: 10.82 (-0.10), KMB: 108.37 (-1.89), AON: 99.63 (-0.29), CB: 100.11 (-0.91), KEY: 13.90 (-0.10), K: 64.72 (-0.04), PEP: 97.36 (-1.04), SWK: 97.32 (-1.06), JNJ: 101.65 (-0.69), AVY: 53.23 (-0.03), CMA: 45.68 (-0.02), PPG: 235.34 (+0.80), KO: 42.50 (-0.45), XEL: 34.58 (-0.11), ABT: 47.01 (-0.08), NUE: 47.41 (+0.26), SVU: 10.18 (+0.28), EMR: 57.78 (-0.60), LEG: 45.37 (-0.38), LLY: 70.65 (+0.28), ITW: 98.20 (-1.47), PLL: 101.79 (-0.70), USB: 44.41 (-0.34), GCI: 34.77 (-0.76), PG: 84.35 (-0.81), JCI: 50.70 (-0.75)
Malignant Glioma Therapeutics Pipeline Review 2015 - 10 Companies & 18 Drug Profiles
M2 - Tue Mar 03, 5:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/5rhrvv/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Eli Lilly and Company - iDD biotech SAS - Lipopharma Therapeutics SL - Merck & Co., Inc. - Nuo Therapeutics, Inc. - Orbus Therapeutics, Inc. - Sanofi - Stemline Therapeutics, Inc. - ZIOPHARM Oncology, Inc. Drug Profiles - Ad-RTS-IL-12 - ALD-451 - Dendritic Cell Therapy for Malignant Gliomas - Dendritic Cell Therapy for Oncology - eflornithine hydrochloride - galunisertib - GliAtak - IDD-004 - LD-224 - marizomib - Minerval - Monoclonal Antibody Conjugated to Antagonize EGFR for Brain Tumor and Glioblastoma Multiforme - pembrolizumab - SL-701 - Small Molecule for Brain Cancer and Malignant Glioma - Vaccine to Target Survivin for Malignant Glioma - Vaccine to Target Wilm's Tumor 1 for Oncology - voxtalisib For more information visit http://www.researchandmarkets.com/research/5r...ant_glioma
ZIOP: 13.34 (+0.85), MRK: 57.88 (-0.46), LLY: 70.65 (+0.28), STML: 16.05 (+0.37)
10 Dandy Dividend Healthcare Dogs Hail 14% February Upsides
Fredrik Arnold - at Seeking Alpha - Tue Mar 03, 5:28AM CST
KND: 22.08 (-0.01), VIVO: 20.06 (+0.06), PETS: 15.08 (-0.05), PFE: 34.64 (+0.08), AMGN: 159.19 (+0.63), GSK: 47.82 (+0.11), MSA: 48.84 (-0.87), PDLI: 6.96 (-0.06), BAX: 69.25 (-0.17), AZN: 67.79 (-0.49), MRK: 57.88 (-0.46), STJ: 67.14 (-0.46), TRIB: 18.60 (+0.17), TEVA: 56.56 (+0.10), ABBV: 60.27 (+0.65), THRX: 19.64 (+0.08), SNY: 48.34 (+0.26)
India Pharma Outlook 2015: Accelerating growth to the next level: Moving up the value chain beyond Generics, New Report Launched
M2 - Tue Mar 03, 5:17AM CST
Market Research Reports, Inc. has announced the addition of "India Pharma Outlook 2015: Accelerating growth to the next level: Moving up the value chain beyond Genericsresearch report to their website http://www.MarketResearchReports.com
MRK: 57.88 (-0.46)
Glaucoma - Pipeline Review, H1 2015 - Featuring 50 Companies & 104 Drug Profiles
M2 - Tue Mar 03, 5:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/8h3k7s/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AC Immune SA - Acadia Pharmaceuticals Inc. - Aerie Pharmaceuticals, Inc. - Alcon, Inc. - Allergan, Inc. - Altacor Ltd. - Amakem NV - Asahi Kasei Pharma Corp. - AUS Bio Limited - Bausch & Lomb Incorporated - Bionure Farma, S.L. - Can-Fite BioPharma Ltd. - Cellular Biomedicine Group, Inc. - China Grand Wuhan General Pharmaceutical Research Institute - D. Western Therapeutics Institute, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - F. Hoffmann-La Roche Ltd. - Foamix Pharmaceuticals Ltd. - Gene Signal International SA - Gilead Sciences, Inc. - Handok Inc. - High Point Pharmaceuticals, LLC - Icon Bioscience, Inc. - IMMD Inc. - Inotek Pharmaceuticals Corporation - InSite Vision Incorporated - Lacer, S.A. - Merck & Co., Inc. - Merz Pharma GmbH & Co. KgaA For more information visit http://www.researchandmarkets.com/research/8h3k7s/glaucoma
CANF: 4.40 (-0.10), AGN: 235.68 (+0.82), ACAD: 38.14 (unch), ITEK: 6.00 (unch), GILD: 103.06 (+0.27), MRK: 57.88 (-0.46), FOMX: 8.97 (-0.05), AERI: 28.80 (+0.20), CBMG: 29.50 (-0.34)
Daktari Closes Funding Round for $15.5 Million
PR Newswire - Mon Mar 02, 4:01PM CST
Daktari Diagnostics, which is commercializing a diagnostic platform to meet the need for accuracy, speed, and simplicity at the point of care, has closed a $15.5 million Series D round of funding from new and existing investors, led by Eastern Capital Limited and the Merck Global Health Innovation Fund. Existing investors Norwich Ventures and Partners Innovation Fund also participated in the investment round. Ferghana Partners (Boston, New York, London) assisted Daktari in raising the financing and served as its placement agent and financial advisor.
MRK: 57.88 (-0.46)
Dyslipidemia Therapeutics Pipeline Review 2015 - 35 Companies & 49 Drug Profiles
M2 - Mon Mar 02, 10:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/4qp3rm/dyslipidemia) has announced the addition of the "Dyslipidemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Arisaph Pharmaceuticals, Inc. - AstraZeneca PLC - Biocon Limited - Cadila Pharmaceuticals Ltd. - Cerenis Therapeutics Holding SA - Chong Kun Dang Pharmaceutical Corp. - CymaBay Therapeutics, Inc. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Dezima Pharma BV - Dr. Reddy's Laboratories Limited - Genfit SA - GlaxoSmithKline plc - Hanmi Pharmaceuticals, Co. Ltd. - High Point Pharmaceuticals, LLC - Intas Pharmaceuticals Ltd. - JW Pharmaceutical Corporation - Kissei Pharmaceutical Co., Ltd. - Kotobuki Pharmaceutical Co., Ltd. - Kowa Company, Ltd. - Lipicard Technologies Limited - Merck & Co., Inc. - Nippon Chemiphar Co., Ltd. - Novartis AG - Pfizer Inc. - Sanofi - Takeda Pharmaceutical Company Limited - Torrent Pharmaceuticals Limited - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/4q...slipidemia
PFE: 34.64 (+0.08), AMGN: 159.19 (+0.63), GSK: 47.82 (+0.11), AZN: 67.79 (-0.49), MRK: 57.88 (-0.46), CBAY: 7.43 (-0.31), NVS: 99.04 (-0.02)
Organic Photovoltaics Markets Report 2015-2022
M2 - Mon Mar 02, 9:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/xf27wv/organic) has announced the addition of the "Organic Photovoltaics Markets 2015-2022" report to their offering. This report explores recent improvements in OPV technologies from materials to device structures, even as the supplier landscape has changed. This report also looks at progress being made toward commercial viability in OPV's target markets, now entering what seems to be a final stage of preparation (demo projects) to clear up visibility on the runway for getting these products into end markets. We also update the competitive scenario between related alternative solar PV technologies (OPV, DSC, and some thin-film varieties) as they jostle for position vying for success in the same places - including the sudden emergence of a potentially strong competitor on the horizon: perovskites. This report includes detailed eight-year forecasts for OPV materials and devices, and for the various markets where we expect OPV to enter the market - or at least where proponents hope it will - from building-integrated (BIPV) and building-applied (BAPV) structures to power-charging devices in various form-factors, from tiny panels to awnings and even conventional panels. This report is designed to be especially valuable for marketing and business development executives involved with solar power technologies as well as the targeted end-markets (BIPV/BAPV and solar chargers), as well as investors seeking to profit from such technologies and the companies behind them. Key Topics Covered: Executive Summary Chapter One: Introduction Chapter Two: Technology Trends in Organic Photovoltaics Chapter Three: Markets for OPV Chapter Four: OPV Vendors and Suppliers, Strategies and Technologies Chapter Five: Eight-Year Forecasts and Market Analysis for OPV Companies Mentioned - AGC (Japan) - Armor Group (France) - BASF (Germany) - Belectric (Germany) - CSEM Brasil (Switzerland/Brazil) - DisaSolar (France) - Eight19 (U.K.) - Heraeus (Germany) - Merck (Germany) - Mitsubishi Chemical (Japan) - Next Energy (United States) - Solarmer (United States) - Sumitomo Chemical (Japan) - Toshiba (Japan) For more information visit http://www.researchandmarkets.com/research/xf27wv/organic
MRK: 57.88 (-0.46)
Investors Are Best To Avoid The IShares Nasdaq Biotechnology ETF
Investing Healthcare - at Seeking Alpha - Mon Mar 02, 9:24AM CST
JNJ: 101.65 (-0.69), BIIB: 414.13 (+1.34), ACAD: 38.14 (unch), SPY: 210.23 (-0.89), PCYC: 230.48 (+13.72), GILD: 103.06 (+0.27), MRK: 57.88 (-0.46), ALXN: 182.53 (+0.02), IBB: 340.09 (+2.17), CELG: 119.57 (+1.10)
Stock Market News for March 02, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Mar 02, 9:10AM CST
Benchmarks ended Friday’s trading session in the red as investors weighed positive housing and consumer confidence data against slowdown in the U.S. economic growth
KMI: 41.04 (-0.05), MNST: 139.54 (-1.15), HLF: 31.45 (+0.21), PFE: 34.64 (+0.08), XOM: 87.18 (-0.44), HPQ: 34.19 (-0.38), JNJ: 101.65 (-0.69), GILD: 103.06 (+0.27), MRK: 57.88 (-0.46), EOG: 90.49 (+0.12), JCP: 7.88 (unch), GPS: 42.03 (+0.05), CVX: 105.16 (unch), AAPL: 128.54 (-0.82), AVGO: 129.40 (+1.18)
NGM Biopharmaceuticals Announces Expansion of Management Team
GlobeNewswire - Mon Mar 02, 8:00AM CST
NGM Biopharmaceuticals, Inc., a privately-held biopharmaceutical company, today announced that Jeff Jonker has been named President and David Woodhouse, Ph.D., has joined the company as Chief Financial Officer, effective immediately.
MRK: 57.88 (-0.46)
Merck to Present at the 35th Annual Cowen Health Care Conference
Business Wire - Mon Mar 02, 7:00AM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Adam Schechter, executive vice president and president, Global Human Health, Merck, is scheduled to present at the 35th Annual Cowen Health Care Conference in Boston on Mar. 3, 2015 at 8:40 a.m. EST. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at http://www.merck.com/investors/events-and-pre.../home.html.
MRK: 57.88 (-0.46)
OLED Display Forecast 2015-2025: The Rise of Plastic and Flexible Displays - AMOLED displays will rise to $16bn by 2020
M2 - Mon Mar 02, 4:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/fjsmtq/oled_display) has announced the addition of the "OLED Display Forecast 2015-2025: the Rise of Plastic and Flexible Displays" report to their offering. The next evolution is plastic and flexible displays. It is expected the first flagship phone with a flexible display to ship in 2017. Based on this scenario, the market for plastic and flexible AMOLED displays will rise to $16bn by 2020. OLED displays are thinner, lighter, and offer better color performances compared to backlit liquid crystal displays (LCD). OLED displays are already mass produced for mobile phones and OLEDs will continue gaining market share against LCD technology. The rise of plastic and flexible displays will be accompanied by a shift from glass substrates to plastic substrates such as polyimide. However, glass-based displays will remain an important technology, especially in TV applications where scale-up and cost reduction are still big challenges. Flat and curved OLED TVs were recently launched by Samsung and LG to critical acclaim. However, manufacturers are hedging their bets by investing in LCD backlights enhanced with quantum dots. These so-called ""quantum dot LCD"" TVs will be positioned as a cheaper upgrade from existing sets. Nevertheless, the market for OLED TV panels will experience steady growth over the next decade, with a projected 25% CAGR. Based on a deep understanding of the technology roadmap and the existing bottlenecks, this report has forecasted the OLED display market in eight segments: - Mobile phone displays - Tablet and notebook displays - TV panels - Automotive and aerospace - Wearable electronics - Industrial and professional displays - Microdisplays - Other applications We have been tracking printed, organic, and flexible electronics since 2001. This report gives a unique perspective on the OLED display market, leveraging the full expertise of our analysts and the direct interviews with companies in the value chain. The report will be useful to: - Players in the OLED value chain who need detailed market forecasts - End users who wish to incorporate plastic and flexible displays in their products - Investors who want a complete overview of the OLED display market - Key features of this report - Executive Summary available as a separate 32 slide presentation (PDF format) - Detailed 10-year forecasts by market segment - Detailed 10-year forecasts by display type (AMOLED rigid glass, AMOLED rigid plastic, AMOLED flexible, PMOLED, segmented, and microdisplays) - The latest progress on printed OLEDs - Listing of OLED material suppliers by country - Technologies and players in the OLED value chain (substrate, backplane, transparent conductor, barrier film) - Company profiles based on direct interviews Key Topics Covered: 1. INTRODUCTION 2. OLED STRATEGIES BY DISPLAY MANUFACTURERS 3. PROGRESS IN PRINTED OLED DISPLAYS 4. MARKET SEGMENTATION FOR OLED DISPLAYS 5. MARKET FORECAST 6. FLEXIBLE SUBSTRATES 7. BACKPLANE TECHNOLOGY 8. FRONTPLANE: OLED LAYERS 9. ITO REPLACEMENT: TRANSPARENT CONDUCTORS 10. BARRIER FILM TECHNOLOGY Companies Mentioned - Agfa - Beijing Aglaia Technology Development Co - Blue Nano - Borun New Material Technology Co. (Borun Chemical Co) - CNano - Cambrios - Canatu - Cheil Industries - Cynora - Daejoo Electronic Materials Company - Doosan Corporation ElectroMaterials - Dow Chemical - DuPont - Idemitsu Kosan - JNC (ex Chisso) - Jilin Optical & Electronic Materials Co - Konica Minolta - LG Chem - Luminescence Technology Co. - Merck - Mitsubishi Chemical Corporation - Mitsui Chemicals - NanoIntegris - Nichem Fine Technology - Nippon Steel & Sumikin Chemical - Nissan Chemical Industries - Novaled - Sun Fine Chemical Co (SFC) - Toray Industries - Universal Display Corporation For more information visit http://www.researchandmarkets.com/research/fj...ed_display
OLED: 36.58 (+0.60), MRK: 57.88 (-0.46), DOW: 49.57 (+0.32)
Billionaire George Soros Just Dumped These 3 Dividend Stocks
George Budwell, The Motley Fool - Motley Fool - Sun Mar 01, 9:55AM CST
Because billionaire investors can have a disproportionately large impact on how markets behave in the short term, their buys and sells tend to be closely scrutinized. And controversial hedge-fund manager George Soros is one of the most widely watched...
GILD: 103.06 (+0.27), MRK: 57.88 (-0.46), AZN: 67.79 (-0.49), TEVA: 56.56 (+0.10), ABBV: 60.27 (+0.65)
Some Companies Are More Wonderful Than Others
Investing Doc - at Seeking Alpha - Sun Mar 01, 4:02AM CST
BBT: 37.81 (-0.36), MON: 119.86 (-0.34), EA: 57.20 (+0.53), HSY: 101.53 (-1.02), ED: 61.87 (-0.30), SYY: 38.81 (-0.09), LM: 57.00 (-0.92), INTC: 34.12 (+0.02), UPS: 100.42 (-1.08), PGR: 26.42 (-0.37), BSX: 16.79 (+0.03), SPY: 210.23 (-0.89), JPM: 62.13 (+0.16), COF: 78.65 (-0.49), FII: 33.73 (+0.21), DE: 90.45 (-0.82), LOW: 74.02 (-0.99), MSFT: 43.05 (-0.23), ROK: 114.85 (-2.28), CSCO: 29.33 (-0.21), MA: 91.71 (+0.74), SYK: 92.37 (-0.07), BCS: 16.03 (+0.37), BCR: 167.66 (+0.48), ISCA: 31.59 (+0.05), RNR: 100.54 (-1.51), PFE: 34.64 (+0.08), WFC: 54.82 (-0.63), MO: 55.79 (-0.67), ISRG: 500.56 (-8.51), CPB: 46.31 (-0.64), SHW: 285.91 (-0.02), CVX: 105.16 (unch), INTU: 97.45 (-0.55), ADSK: 62.52 (-0.18), NVS: 99.04 (-0.02), GD: 136.25 (-0.84), MMM: 167.16 (-1.11), BDX: 148.36 (+2.10), GE: 25.66 (-0.20), CHRW: 73.96 (-0.71), CLX: 109.93 (-0.91), MDT: 78.19 (+0.16), BLK: 369.14 (-4.52), KMB: 108.37 (-1.89), C: 53.67 (-0.06), KEY: 13.90 (-0.10), MMC: 56.45 (-0.56), JNJ: 101.65 (-0.69), CME: 96.49 (-0.61), CINF: 52.37 (-0.43), PPG: 235.34 (+0.80), BMO: 61.32 (+0.29), FITB: 19.28 (-0.21), HD: 114.76 (-1.31), WU: 19.65 (-0.07), GGG: 75.70 (-1.28), EMR: 57.78 (-0.60), BMY: 65.67 (+3.75), CTAS: 83.77 (-0.44), JOE: 16.85 (-0.20), USB: 44.41 (-0.34), PG: 84.35 (-0.81), IGT: 17.96 (-0.03), BEN: 53.33 (-0.51), CMCSA: 60.43 (+0.47), MXIM: 35.39 (+0.30), RF: 9.55 (-0.07), MKC: 74.84 (-0.41), UTX: 121.04 (-0.66), MTB: 122.45 (-0.28), WMT: 82.58 (-0.79), GOOG: 573.37 (-0.27), SLB: 85.14 (+0.23), SLM: 9.46 (-0.09), TGT: 77.72 (-0.28), LYG: 4.88 (-0.04), FWRD: 52.77 (-0.31), CLMS: 12.62 (+0.22), STR: 23.04 (-0.19), AVP: 9.10 (+0.28), STT: 75.13 (-0.24), VFC: 76.49 (-0.20), LLTC: 47.55 (-0.65), IRM: 36.49 (-0.90), MHFI: 102.55 (-1.07), FDO: 78.59 (-0.07), GSK: 47.82 (+0.11), TIF: 86.79 (-2.15), ADP: 86.57 (-2.13), WBA: 83.02 (-0.19), SIAL: 138.13 (-0.07), MRK: 57.88 (-0.46), EXPD: 47.99 (-0.09), MCD: 100.25 (+0.51), DOV: 71.63 (-0.50), BRK.B: 144.92 (-1.01), WTW: 9.97 (-0.62), CTL: 36.25 (-1.43), BIIB: 414.13 (+1.34), LMT: 198.97 (-0.96), XOM: 87.18 (-0.44), PEP: 97.36 (-1.04), TWX: 83.08 (-0.08), SWK: 97.32 (-1.06), SBUX: 93.06 (-0.94), PAYX: 48.79 (-0.54), FAST: 39.82 (-1.28), EBAY: 58.31 (+0.05), QCOM: 70.85 (-0.55), DIA: 180.78 (-1.09), SNV: 27.34 (-0.13), AVY: 53.23 (-0.03), SNY: 48.34 (+0.26), BK: 39.44 (-0.21), HRB: 33.42 (-0.29), KO: 42.50 (-0.45), AXP: 80.63 (-1.28), SVU: 10.18 (+0.28), NUE: 47.41 (+0.26), LEG: 45.37 (-0.38), AMGN: 159.19 (+0.63), DIS: 105.57 (-0.78), BAC: 15.84 (-0.20), ORCL: 43.61 (+0.23), BRO: 31.75 (-0.17), JCI: 50.70 (-0.75), CL: 70.68 (unch)
This Billionaire CEO Just Made Another Biotech Acquisition -- and Hardly Anyone Noticed
Maxx Chatsko, The Motley Fool - Motley Fool - Sat Feb 28, 1:08PM CST
Investors have rushed to acquire shares of synthetic biology company Intrexon in the first two months of 2015. Most of the enthusiasm stems from a recent partnership with the University of Texas MD Anderson Cancer Center and Ziopharm to...
ZIOP: 13.34 (+0.85), MRK: 57.88 (-0.46), XON: 48.11 (-0.04)
Bristol-Myers Lung Cancer Drug Opdivo Wins Speedy OK
at Investor's Business Daily - Wed Mar 04, 2:28PM CST
The Food and Drug Administration approved Bristol-Myers Squibb's (BMY) PD-1 inhibitor Opdivo for squamous-cell lung cancer Wednesday, well ahead of the expected timeline. The stock jumped to a 14-year high near 65. Opdivo was first approved for...
AZN: 67.79 (-0.49), MRK: 57.88 (-0.46), BMY: 65.67 (+3.75)
Bristol-Myers Backs Bavarian Nordic Cancer Vaccine
at Investor's Business Daily - Wed Mar 04, 10:12AM CST
Big pharma Bristol-Myers Squibb (BMY) said Wednesday that it inked a deal worth up to $975 million with Danish biotech Bavarian Nordic for its prostate-cancer vaccine candidate Prostvac, a step forward for a technology that still has yet to prove...
AZN: 67.79 (-0.49), MRK: 57.88 (-0.46), BMY: 65.67 (+3.75)
Geron's Q4 Loss Narrows Y/Y, Announces Restructuring Plan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 9:50AM CST
Geron Corporation (GERN) reported a fourth-quarter 2014 loss of 6 cents per share, a penny narrower than the year-ago loss of 7 cents. The Zacks Consensus Estimate was earnings of 17 cents.
JNJ: 101.65 (-0.69), GERN: 2.81 (-0.15), MRK: 57.88 (-0.46), BMY: 65.67 (+3.75)
Amgen: The Best Biotech Stock You Don't Own
Dan Strack - at Seeking Alpha - Tue Mar 03, 4:04PM CST
BIIB: 414.13 (+1.34), GILD: 103.06 (+0.27), PFE: 34.64 (+0.08), MRK: 57.88 (-0.46), AMGN: 159.19 (+0.63), ABBV: 60.27 (+0.65), GSK: 47.82 (+0.11), BMY: 65.67 (+3.75), HSP: 87.95 (+0.24), NVS: 99.04 (-0.02), CELG: 119.57 (+1.10)
5 Common Errors Of A Dividend Growth Forecast
Kurtis Hemmerling - at Seeking Alpha - Tue Mar 03, 7:52AM CST
HI: 31.17 (-0.71), RF: 9.55 (-0.07), HSY: 101.53 (-1.02), GPC: 94.04 (-1.47), CAG: 34.52 (-0.44), ED: 61.87 (-0.30), SYY: 38.81 (-0.09), RRD: 19.54 (+0.23), GWW: 236.00 (-5.29), TGT: 77.72 (-0.28), LOW: 74.02 (-0.99), BCR: 167.66 (+0.48), PFE: 34.64 (+0.08), VFC: 76.49 (-0.20), FDO: 78.59 (-0.07), MHFI: 102.55 (-1.07), MO: 55.79 (-0.67), WBA: 83.02 (-0.19), ADP: 86.57 (-2.13), ADM: 47.08 (-0.44), SIAL: 138.13 (-0.07), MRK: 57.88 (-0.46), MCD: 100.25 (+0.51), DOV: 71.63 (-0.50), CTL: 36.25 (-1.43), MMM: 167.16 (-1.11), TE: 19.23 (-0.05), GE: 25.66 (-0.20), BDX: 148.36 (+2.10), HBAN: 10.82 (-0.10), KMB: 108.37 (-1.89), AON: 99.63 (-0.29), CB: 100.11 (-0.91), KEY: 13.90 (-0.10), K: 64.72 (-0.04), PEP: 97.36 (-1.04), SWK: 97.32 (-1.06), JNJ: 101.65 (-0.69), AVY: 53.23 (-0.03), CMA: 45.68 (-0.02), PPG: 235.34 (+0.80), KO: 42.50 (-0.45), XEL: 34.58 (-0.11), ABT: 47.01 (-0.08), NUE: 47.41 (+0.26), SVU: 10.18 (+0.28), EMR: 57.78 (-0.60), LEG: 45.37 (-0.38), LLY: 70.65 (+0.28), ITW: 98.20 (-1.47), PLL: 101.79 (-0.70), USB: 44.41 (-0.34), GCI: 34.77 (-0.76), PG: 84.35 (-0.81), JCI: 50.70 (-0.75)
Malignant Glioma Therapeutics Pipeline Review 2015 - 10 Companies & 18 Drug Profiles
M2 - Tue Mar 03, 5:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/5rhrvv/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Eli Lilly and Company - iDD biotech SAS - Lipopharma Therapeutics SL - Merck & Co., Inc. - Nuo Therapeutics, Inc. - Orbus Therapeutics, Inc. - Sanofi - Stemline Therapeutics, Inc. - ZIOPHARM Oncology, Inc. Drug Profiles - Ad-RTS-IL-12 - ALD-451 - Dendritic Cell Therapy for Malignant Gliomas - Dendritic Cell Therapy for Oncology - eflornithine hydrochloride - galunisertib - GliAtak - IDD-004 - LD-224 - marizomib - Minerval - Monoclonal Antibody Conjugated to Antagonize EGFR for Brain Tumor and Glioblastoma Multiforme - pembrolizumab - SL-701 - Small Molecule for Brain Cancer and Malignant Glioma - Vaccine to Target Survivin for Malignant Glioma - Vaccine to Target Wilm's Tumor 1 for Oncology - voxtalisib For more information visit http://www.researchandmarkets.com/research/5r...ant_glioma
ZIOP: 13.34 (+0.85), MRK: 57.88 (-0.46), LLY: 70.65 (+0.28), STML: 16.05 (+0.37)
10 Dandy Dividend Healthcare Dogs Hail 14% February Upsides
Fredrik Arnold - at Seeking Alpha - Tue Mar 03, 5:28AM CST
KND: 22.08 (-0.01), VIVO: 20.06 (+0.06), PETS: 15.08 (-0.05), PFE: 34.64 (+0.08), AMGN: 159.19 (+0.63), GSK: 47.82 (+0.11), MSA: 48.84 (-0.87), PDLI: 6.96 (-0.06), BAX: 69.25 (-0.17), AZN: 67.79 (-0.49), MRK: 57.88 (-0.46), STJ: 67.14 (-0.46), TRIB: 18.60 (+0.17), TEVA: 56.56 (+0.10), ABBV: 60.27 (+0.65), THRX: 19.64 (+0.08), SNY: 48.34 (+0.26)
India Pharma Outlook 2015: Accelerating growth to the next level: Moving up the value chain beyond Generics, New Report Launched
M2 - Tue Mar 03, 5:17AM CST
Market Research Reports, Inc. has announced the addition of "India Pharma Outlook 2015: Accelerating growth to the next level: Moving up the value chain beyond Genericsresearch report to their website http://www.MarketResearchReports.com
MRK: 57.88 (-0.46)
Glaucoma - Pipeline Review, H1 2015 - Featuring 50 Companies & 104 Drug Profiles
M2 - Tue Mar 03, 5:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/8h3k7s/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AC Immune SA - Acadia Pharmaceuticals Inc. - Aerie Pharmaceuticals, Inc. - Alcon, Inc. - Allergan, Inc. - Altacor Ltd. - Amakem NV - Asahi Kasei Pharma Corp. - AUS Bio Limited - Bausch & Lomb Incorporated - Bionure Farma, S.L. - Can-Fite BioPharma Ltd. - Cellular Biomedicine Group, Inc. - China Grand Wuhan General Pharmaceutical Research Institute - D. Western Therapeutics Institute, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - F. Hoffmann-La Roche Ltd. - Foamix Pharmaceuticals Ltd. - Gene Signal International SA - Gilead Sciences, Inc. - Handok Inc. - High Point Pharmaceuticals, LLC - Icon Bioscience, Inc. - IMMD Inc. - Inotek Pharmaceuticals Corporation - InSite Vision Incorporated - Lacer, S.A. - Merck & Co., Inc. - Merz Pharma GmbH & Co. KgaA For more information visit http://www.researchandmarkets.com/research/8h3k7s/glaucoma
CANF: 4.40 (-0.10), AGN: 235.68 (+0.82), ACAD: 38.14 (unch), ITEK: 6.00 (unch), GILD: 103.06 (+0.27), MRK: 57.88 (-0.46), FOMX: 8.97 (-0.05), AERI: 28.80 (+0.20), CBMG: 29.50 (-0.34)
Daktari Closes Funding Round for $15.5 Million
PR Newswire - Mon Mar 02, 4:01PM CST
Daktari Diagnostics, which is commercializing a diagnostic platform to meet the need for accuracy, speed, and simplicity at the point of care, has closed a $15.5 million Series D round of funding from new and existing investors, led by Eastern Capital Limited and the Merck Global Health Innovation Fund. Existing investors Norwich Ventures and Partners Innovation Fund also participated in the investment round. Ferghana Partners (Boston, New York, London) assisted Daktari in raising the financing and served as its placement agent and financial advisor.
MRK: 57.88 (-0.46)
Dyslipidemia Therapeutics Pipeline Review 2015 - 35 Companies & 49 Drug Profiles
M2 - Mon Mar 02, 10:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/4qp3rm/dyslipidemia) has announced the addition of the "Dyslipidemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dyslipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyslipidemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Arisaph Pharmaceuticals, Inc. - AstraZeneca PLC - Biocon Limited - Cadila Pharmaceuticals Ltd. - Cerenis Therapeutics Holding SA - Chong Kun Dang Pharmaceutical Corp. - CymaBay Therapeutics, Inc. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Dezima Pharma BV - Dr. Reddy's Laboratories Limited - Genfit SA - GlaxoSmithKline plc - Hanmi Pharmaceuticals, Co. Ltd. - High Point Pharmaceuticals, LLC - Intas Pharmaceuticals Ltd. - JW Pharmaceutical Corporation - Kissei Pharmaceutical Co., Ltd. - Kotobuki Pharmaceutical Co., Ltd. - Kowa Company, Ltd. - Lipicard Technologies Limited - Merck & Co., Inc. - Nippon Chemiphar Co., Ltd. - Novartis AG - Pfizer Inc. - Sanofi - Takeda Pharmaceutical Company Limited - Torrent Pharmaceuticals Limited - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/4q...slipidemia
PFE: 34.64 (+0.08), AMGN: 159.19 (+0.63), GSK: 47.82 (+0.11), AZN: 67.79 (-0.49), MRK: 57.88 (-0.46), CBAY: 7.43 (-0.31), NVS: 99.04 (-0.02)
Organic Photovoltaics Markets Report 2015-2022
M2 - Mon Mar 02, 9:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/xf27wv/organic) has announced the addition of the "Organic Photovoltaics Markets 2015-2022" report to their offering. This report explores recent improvements in OPV technologies from materials to device structures, even as the supplier landscape has changed. This report also looks at progress being made toward commercial viability in OPV's target markets, now entering what seems to be a final stage of preparation (demo projects) to clear up visibility on the runway for getting these products into end markets. We also update the competitive scenario between related alternative solar PV technologies (OPV, DSC, and some thin-film varieties) as they jostle for position vying for success in the same places - including the sudden emergence of a potentially strong competitor on the horizon: perovskites. This report includes detailed eight-year forecasts for OPV materials and devices, and for the various markets where we expect OPV to enter the market - or at least where proponents hope it will - from building-integrated (BIPV) and building-applied (BAPV) structures to power-charging devices in various form-factors, from tiny panels to awnings and even conventional panels. This report is designed to be especially valuable for marketing and business development executives involved with solar power technologies as well as the targeted end-markets (BIPV/BAPV and solar chargers), as well as investors seeking to profit from such technologies and the companies behind them. Key Topics Covered: Executive Summary Chapter One: Introduction Chapter Two: Technology Trends in Organic Photovoltaics Chapter Three: Markets for OPV Chapter Four: OPV Vendors and Suppliers, Strategies and Technologies Chapter Five: Eight-Year Forecasts and Market Analysis for OPV Companies Mentioned - AGC (Japan) - Armor Group (France) - BASF (Germany) - Belectric (Germany) - CSEM Brasil (Switzerland/Brazil) - DisaSolar (France) - Eight19 (U.K.) - Heraeus (Germany) - Merck (Germany) - Mitsubishi Chemical (Japan) - Next Energy (United States) - Solarmer (United States) - Sumitomo Chemical (Japan) - Toshiba (Japan) For more information visit http://www.researchandmarkets.com/research/xf27wv/organic
MRK: 57.88 (-0.46)
Investors Are Best To Avoid The IShares Nasdaq Biotechnology ETF
Investing Healthcare - at Seeking Alpha - Mon Mar 02, 9:24AM CST
JNJ: 101.65 (-0.69), BIIB: 414.13 (+1.34), ACAD: 38.14 (unch), SPY: 210.23 (-0.89), PCYC: 230.48 (+13.72), GILD: 103.06 (+0.27), MRK: 57.88 (-0.46), ALXN: 182.53 (+0.02), IBB: 340.09 (+2.17), CELG: 119.57 (+1.10)
Stock Market News for March 02, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Mar 02, 9:10AM CST
Benchmarks ended Friday’s trading session in the red as investors weighed positive housing and consumer confidence data against slowdown in the U.S. economic growth
KMI: 41.04 (-0.05), MNST: 139.54 (-1.15), HLF: 31.45 (+0.21), PFE: 34.64 (+0.08), XOM: 87.18 (-0.44), HPQ: 34.19 (-0.38), JNJ: 101.65 (-0.69), GILD: 103.06 (+0.27), MRK: 57.88 (-0.46), EOG: 90.49 (+0.12), JCP: 7.88 (unch), GPS: 42.03 (+0.05), CVX: 105.16 (unch), AAPL: 128.54 (-0.82), AVGO: 129.40 (+1.18)
NGM Biopharmaceuticals Announces Expansion of Management Team
GlobeNewswire - Mon Mar 02, 8:00AM CST
NGM Biopharmaceuticals, Inc., a privately-held biopharmaceutical company, today announced that Jeff Jonker has been named President and David Woodhouse, Ph.D., has joined the company as Chief Financial Officer, effective immediately.
MRK: 57.88 (-0.46)
Merck to Present at the 35th Annual Cowen Health Care Conference
Business Wire - Mon Mar 02, 7:00AM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Adam Schechter, executive vice president and president, Global Human Health, Merck, is scheduled to present at the 35th Annual Cowen Health Care Conference in Boston on Mar. 3, 2015 at 8:40 a.m. EST. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at http://www.merck.com/investors/events-and-pre.../home.html.
MRK: 57.88 (-0.46)
OLED Display Forecast 2015-2025: The Rise of Plastic and Flexible Displays - AMOLED displays will rise to $16bn by 2020
M2 - Mon Mar 02, 4:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/fjsmtq/oled_display) has announced the addition of the "OLED Display Forecast 2015-2025: the Rise of Plastic and Flexible Displays" report to their offering. The next evolution is plastic and flexible displays. It is expected the first flagship phone with a flexible display to ship in 2017. Based on this scenario, the market for plastic and flexible AMOLED displays will rise to $16bn by 2020. OLED displays are thinner, lighter, and offer better color performances compared to backlit liquid crystal displays (LCD). OLED displays are already mass produced for mobile phones and OLEDs will continue gaining market share against LCD technology. The rise of plastic and flexible displays will be accompanied by a shift from glass substrates to plastic substrates such as polyimide. However, glass-based displays will remain an important technology, especially in TV applications where scale-up and cost reduction are still big challenges. Flat and curved OLED TVs were recently launched by Samsung and LG to critical acclaim. However, manufacturers are hedging their bets by investing in LCD backlights enhanced with quantum dots. These so-called ""quantum dot LCD"" TVs will be positioned as a cheaper upgrade from existing sets. Nevertheless, the market for OLED TV panels will experience steady growth over the next decade, with a projected 25% CAGR. Based on a deep understanding of the technology roadmap and the existing bottlenecks, this report has forecasted the OLED display market in eight segments: - Mobile phone displays - Tablet and notebook displays - TV panels - Automotive and aerospace - Wearable electronics - Industrial and professional displays - Microdisplays - Other applications We have been tracking printed, organic, and flexible electronics since 2001. This report gives a unique perspective on the OLED display market, leveraging the full expertise of our analysts and the direct interviews with companies in the value chain. The report will be useful to: - Players in the OLED value chain who need detailed market forecasts - End users who wish to incorporate plastic and flexible displays in their products - Investors who want a complete overview of the OLED display market - Key features of this report - Executive Summary available as a separate 32 slide presentation (PDF format) - Detailed 10-year forecasts by market segment - Detailed 10-year forecasts by display type (AMOLED rigid glass, AMOLED rigid plastic, AMOLED flexible, PMOLED, segmented, and microdisplays) - The latest progress on printed OLEDs - Listing of OLED material suppliers by country - Technologies and players in the OLED value chain (substrate, backplane, transparent conductor, barrier film) - Company profiles based on direct interviews Key Topics Covered: 1. INTRODUCTION 2. OLED STRATEGIES BY DISPLAY MANUFACTURERS 3. PROGRESS IN PRINTED OLED DISPLAYS 4. MARKET SEGMENTATION FOR OLED DISPLAYS 5. MARKET FORECAST 6. FLEXIBLE SUBSTRATES 7. BACKPLANE TECHNOLOGY 8. FRONTPLANE: OLED LAYERS 9. ITO REPLACEMENT: TRANSPARENT CONDUCTORS 10. BARRIER FILM TECHNOLOGY Companies Mentioned - Agfa - Beijing Aglaia Technology Development Co - Blue Nano - Borun New Material Technology Co. (Borun Chemical Co) - CNano - Cambrios - Canatu - Cheil Industries - Cynora - Daejoo Electronic Materials Company - Doosan Corporation ElectroMaterials - Dow Chemical - DuPont - Idemitsu Kosan - JNC (ex Chisso) - Jilin Optical & Electronic Materials Co - Konica Minolta - LG Chem - Luminescence Technology Co. - Merck - Mitsubishi Chemical Corporation - Mitsui Chemicals - NanoIntegris - Nichem Fine Technology - Nippon Steel & Sumikin Chemical - Nissan Chemical Industries - Novaled - Sun Fine Chemical Co (SFC) - Toray Industries - Universal Display Corporation For more information visit http://www.researchandmarkets.com/research/fj...ed_display
OLED: 36.58 (+0.60), MRK: 57.88 (-0.46), DOW: 49.57 (+0.32)
Billionaire George Soros Just Dumped These 3 Dividend Stocks
George Budwell, The Motley Fool - Motley Fool - Sun Mar 01, 9:55AM CST
Because billionaire investors can have a disproportionately large impact on how markets behave in the short term, their buys and sells tend to be closely scrutinized. And controversial hedge-fund manager George Soros is one of the most widely watched...
GILD: 103.06 (+0.27), MRK: 57.88 (-0.46), AZN: 67.79 (-0.49), TEVA: 56.56 (+0.10), ABBV: 60.27 (+0.65)
Some Companies Are More Wonderful Than Others
Investing Doc - at Seeking Alpha - Sun Mar 01, 4:02AM CST
BBT: 37.81 (-0.36), MON: 119.86 (-0.34), EA: 57.20 (+0.53), HSY: 101.53 (-1.02), ED: 61.87 (-0.30), SYY: 38.81 (-0.09), LM: 57.00 (-0.92), INTC: 34.12 (+0.02), UPS: 100.42 (-1.08), PGR: 26.42 (-0.37), BSX: 16.79 (+0.03), SPY: 210.23 (-0.89), JPM: 62.13 (+0.16), COF: 78.65 (-0.49), FII: 33.73 (+0.21), DE: 90.45 (-0.82), LOW: 74.02 (-0.99), MSFT: 43.05 (-0.23), ROK: 114.85 (-2.28), CSCO: 29.33 (-0.21), MA: 91.71 (+0.74), SYK: 92.37 (-0.07), BCS: 16.03 (+0.37), BCR: 167.66 (+0.48), ISCA: 31.59 (+0.05), RNR: 100.54 (-1.51), PFE: 34.64 (+0.08), WFC: 54.82 (-0.63), MO: 55.79 (-0.67), ISRG: 500.56 (-8.51), CPB: 46.31 (-0.64), SHW: 285.91 (-0.02), CVX: 105.16 (unch), INTU: 97.45 (-0.55), ADSK: 62.52 (-0.18), NVS: 99.04 (-0.02), GD: 136.25 (-0.84), MMM: 167.16 (-1.11), BDX: 148.36 (+2.10), GE: 25.66 (-0.20), CHRW: 73.96 (-0.71), CLX: 109.93 (-0.91), MDT: 78.19 (+0.16), BLK: 369.14 (-4.52), KMB: 108.37 (-1.89), C: 53.67 (-0.06), KEY: 13.90 (-0.10), MMC: 56.45 (-0.56), JNJ: 101.65 (-0.69), CME: 96.49 (-0.61), CINF: 52.37 (-0.43), PPG: 235.34 (+0.80), BMO: 61.32 (+0.29), FITB: 19.28 (-0.21), HD: 114.76 (-1.31), WU: 19.65 (-0.07), GGG: 75.70 (-1.28), EMR: 57.78 (-0.60), BMY: 65.67 (+3.75), CTAS: 83.77 (-0.44), JOE: 16.85 (-0.20), USB: 44.41 (-0.34), PG: 84.35 (-0.81), IGT: 17.96 (-0.03), BEN: 53.33 (-0.51), CMCSA: 60.43 (+0.47), MXIM: 35.39 (+0.30), RF: 9.55 (-0.07), MKC: 74.84 (-0.41), UTX: 121.04 (-0.66), MTB: 122.45 (-0.28), WMT: 82.58 (-0.79), GOOG: 573.37 (-0.27), SLB: 85.14 (+0.23), SLM: 9.46 (-0.09), TGT: 77.72 (-0.28), LYG: 4.88 (-0.04), FWRD: 52.77 (-0.31), CLMS: 12.62 (+0.22), STR: 23.04 (-0.19), AVP: 9.10 (+0.28), STT: 75.13 (-0.24), VFC: 76.49 (-0.20), LLTC: 47.55 (-0.65), IRM: 36.49 (-0.90), MHFI: 102.55 (-1.07), FDO: 78.59 (-0.07), GSK: 47.82 (+0.11), TIF: 86.79 (-2.15), ADP: 86.57 (-2.13), WBA: 83.02 (-0.19), SIAL: 138.13 (-0.07), MRK: 57.88 (-0.46), EXPD: 47.99 (-0.09), MCD: 100.25 (+0.51), DOV: 71.63 (-0.50), BRK.B: 144.92 (-1.01), WTW: 9.97 (-0.62), CTL: 36.25 (-1.43), BIIB: 414.13 (+1.34), LMT: 198.97 (-0.96), XOM: 87.18 (-0.44), PEP: 97.36 (-1.04), TWX: 83.08 (-0.08), SWK: 97.32 (-1.06), SBUX: 93.06 (-0.94), PAYX: 48.79 (-0.54), FAST: 39.82 (-1.28), EBAY: 58.31 (+0.05), QCOM: 70.85 (-0.55), DIA: 180.78 (-1.09), SNV: 27.34 (-0.13), AVY: 53.23 (-0.03), SNY: 48.34 (+0.26), BK: 39.44 (-0.21), HRB: 33.42 (-0.29), KO: 42.50 (-0.45), AXP: 80.63 (-1.28), SVU: 10.18 (+0.28), NUE: 47.41 (+0.26), LEG: 45.37 (-0.38), AMGN: 159.19 (+0.63), DIS: 105.57 (-0.78), BAC: 15.84 (-0.20), ORCL: 43.61 (+0.23), BRO: 31.75 (-0.17), JCI: 50.70 (-0.75), CL: 70.68 (unch)
This Billionaire CEO Just Made Another Biotech Acquisition -- and Hardly Anyone Noticed
Maxx Chatsko, The Motley Fool - Motley Fool - Sat Feb 28, 1:08PM CST
Investors have rushed to acquire shares of synthetic biology company Intrexon in the first two months of 2015. Most of the enthusiasm stems from a recent partnership with the University of Texas MD Anderson Cancer Center and Ziopharm to...
ZIOP: 13.34 (+0.85), MRK: 57.88 (-0.46), XON: 48.11 (-0.04)
